Macular degeneration treatment linked to blindness, FDA advisory says

Share this article:

Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.

Twelve patients in at least three separate clinics developed the serious bacterial infection Streptococcus endophthalmitis after undergoing injections of Avastin, which is administered in tiny doses to the eye, according to a Food and Drug Administration advisory issued Aug. 30. At least five of these patients have lost all remaining vision in the eyes that were treated with Avastin.

The infections have been traced back to a compounding pharmacy in Hollywood, FL, which repackaged intravitreal injections of Avastin from injectable 100-mg/4- mL, single-use vials into individual 1-mL single-use syringes. Officials say the repackaging process can open the door for bacterial contamination.

This is another blow to Avastin as an eye treatment. Recent studies have found Avastin to be as effective as its competitor Lucentis in treating macular degeneration in seniors, for a fraction of the price. Lucentis costs $2,000 per injection while Avastin costs just $50 per dose. Genentech manufactures both drugs.

Share this article:

More in News

Nursing home did not warn worker who was taken hostage in active ...

A nurse at a Life Care Centers of America facility in Colorado was not notified that she would be threatened and taken hostage by a gunman as part of an active shooter drill, according to a lawsuit filed Tuesday.

Revisions to False Claims Act urged by former deputy AG

A panel of witnesses debated the merits of the False Claims Act before a Judiciary subcommittee meeting Wednesday, with one former attorney general arguing current policy provokes unfair litigation and "coercive" settlements.

Medicare SNF rate finalized, reimbursements to increase by $750 million next year

Medicare SNF rate finalized, reimbursements to increase by ...

Medicare skilled nursing facility reimbursements will increase by $750 million next year under a final payment rule announced Thursday by the Centers for Medicare & Medicaid Services.